Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone Effect on Mitochondria and Lipoatrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lipoatrophy~* Thymidine sparing ARV for at least 24 weeks~* Prior thymidine NRTIs for at least 12 months~Exclusion Criteria:~* Diabetes~* Heart failure~* Liver disease~* Hormonal therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosigitazone arm (Type: ACTIVE_COMPARATOR): Rosiglitazone active 4 mg BID
- Placebo arm (Type: PLACEBO_COMPARATOR): Matching Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).